eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
 
1/2006
vol. 44
 
Share:
Share:
more
 
 
abstract:

ORIGINAL ARTICLE
Leflunomide in treatment of RA patents preliminary estimation of therapeutical efficiency and side effects

Maria Rell-Bakalarska
,
Janusz Jaworski
,
Lidia Rutkowska-Sak
,
Małgorzata Wieczorek
,
Małgorzata Kwiatkowska
,
Ewa Klimczak
,
Bożena Kowalczuk
,
Krzysztof Wojciech Rell

RU 2006; 44, 1: 19-25
Online publish date: 2006/02/15
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
In the preliminary estimation there were studied efficiency and safety of therapy leflunomid in patients with RA. The drug was given p. o. to a group of 158 patients (150 females and 8 males) for 3 days 100 mg/24 h, and then again 20 mg/24 h.
The age of patients varied between 19-78 (average age was 55 years), with average duration time of the disease 10 years and 2 months. All of the patients were previously unsuccessfully treated with other DMARDS. All of the patients had high activity of disease estimated by DAS 28 ≥5.1 61.4% of patients were treated with long-term glicocorticosteroids. Time of trial was scheduled for 6 months. The therapeutical effect was initially estimated on the basis of a group of 43 patients who took the medicine for 91-120 days.
Good and average therapeutical efficiency of treatment was observed in 76.73% of patients. Efficiency was expressed by lowering DAS 28 by 0.6-1.2 in a group of 11.62% of patients and 1.2 in a group of 65.11% of patients. In a group of 3.79% of patients the treatment was stopped because of complete lack of therapeutical effect.
Frequency of side effects was initially estimated in a group of 158 patients.
Treatment was interrupted in the group of 8.86% of patients because of such side effects as: diarrheas, elevation of transaminazes, leukopenia and trombocytopenia, skin changes and dizziness. Observations are continued. Preliminary results of observations allow for positive evaluation of treatment with leflunomid in RA patients.
keywords:

rheumatoid arthritis, diseases modifying antirheumatic drugs, therapeutical effect







Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe